8-K: Annexon Reports Q2 2025 Results, Key Milestones

Annexon, Inc. announced its second quarter 2025 financial results and highlighted significant progress across its late-stage clinical pipeline, including anticipated regulatory submissions and trial data readouts.

Summary

• Reported second quarter 2025 financial results and portfolio progress.
• Cash and cash equivalents and short-term investments totaled $227.0 million as of June 30, 2025.
• Cash runway is expected to fund operations into the fourth quarter of 2026, through Vonaprument topline Phase 3 data.
• Research and development (R&D) expenses increased to $44.2 million for Q2 2025 from $25.0 million for Q2 2024.
• General and administrative (G&A) expenses decreased to $7.6 million for Q2 2025 from $8.6 million for Q2 2024.
• Net loss for Q2 2025 was $49.2 million, or $0.34 per share, compared to $29.6 million, or $0.23 per share, for Q2 2024.
• Tanruprubart (ANX005) for GBS is advancing with a Marketing Authorization Application (MAA) submission to the European Medicines Agency (EMA) anticipated in the first quarter of 2026.
• Ongoing discussions with the FDA regarding a generalizability package to support a Biologics License Application (BLA) submission for Tanruprubart.
• Enrollment for the global Phase 3 ARCHER II trial of Vonaprument (ANX007) for Dry AMD with GA has been completed with 659 patients.
• Topline ARCHER II data for Vonaprument is expected in the second half of 2026.
• ANX1502, an oral C1s inhibitor, exceeded target concentration in fasted patients in its proof-of-concept (POC) CAD study, with an update expected by year-end 2025.

Sentiment

Score: 6

Explanation: The company reported significant clinical progress across its late-stage pipeline, including positive Phase 3 data for Tanruprubart and accelerated enrollment for Vonaprument's pivotal trial, alongside a cash runway extending into Q4 2026. However, the net loss and R&D expenses have substantially increased, indicating a higher burn rate as programs advance, which could necessitate future capital raises beyond the current runway.

Positives

• Strong cash position of $227.0 million as of June 30, 2025, providing runway into Q4 2026, covering key Phase 3 data readout.
• Tanruprubart (ANX005) for GBS showed positive Phase 3 results with approximately 90% of treated patients improving by week 1 and more than twice as many achieving a normal state of health at week 26 vs. placebo.
• Accelerated enrollment completion for the global Phase 3 ARCHER II trial of Vonaprument (ANX007) for Dry AMD with GA, indicating efficient trial execution.
• Vonaprument (ANX007) was selected by EMA for the exclusive Product Development Coordinator (PDC) pilot, which could expedite regulatory interactions and MAA submission readiness.
• ANX1502, a first-in-kind oral C1s inhibitor, demonstrated exposure exceeding target concentration in fasted patients, a positive early sign for its proof-of-concept study.
• Appointment of Lloyd Clark, M.D., as SVP, ophthalmology strategy and innovation, bolstering expertise in a key therapeutic area.
• Established global registration path for Vonaprument with U.S. and European regulators.

Negatives

• Net loss increased significantly to $49.2 million in Q2 2025 from $29.6 million in Q2 2024.
• Research and development (R&D) expenses increased substantially to $44.2 million in Q2 2025 from $25.0 million in Q2 2024, reflecting increased program advancement costs.
• Ongoing discussions with the FDA for Tanruprubart's BLA submission generalizability package indicate potential regulatory hurdles or lack of immediate clarity.
• The company has a history of net operating losses.

Risks

• Final results from the Phase 3 ARCHER II trial may not be positive.
• History of net operating losses.
• Ability to obtain necessary capital to fund clinical programs.
• Potential for delays in clinical trials, including if the FDA and comparable foreign regulatory authorities do not accept data from clinical trials for product candidates outside the United States.
• Early stages of clinical development for some product candidates.
• Effects of public health crises on clinical programs and business operations.
• Ability to obtain regulatory approval of and successfully commercialize product candidates.
• Undesirable side effects or other properties of product candidates.
• Reliance on third-party suppliers and manufacturers.
• Outcomes of any future collaboration agreements may not be favorable.
• Ability to adequately maintain intellectual property rights for product candidates.

Future Outlook

Annexon anticipates submitting its Marketing Authorization Application (MAA) for Tanruprubart in Europe in the first quarter of 2026 and expects topline Phase 3 ARCHER II trial data for Vonaprument in the second half of 2026. An update on the ANX1502 proof-of-concept trial in cold agglutinin disease is expected by year-end 2025. The company projects its current cash and investments will fund operations into the fourth quarter of 2026.

Management Comments

• "We are well positioned to achieve our mission of helping millions of people with devastating complement-mediated diseases live their best lives by the consistent validation generated by our innovative C1 platform across multiple potential best-in-class therapeutics." Douglas Love, President and CEO.
• "In Guillain-Barr Syndrome (GBS), approximately 90% of tanruprubart-treated patients improved by week 1 and more than twice as many patients achieved a normal state of health at week 26 vs. placebo in our Phase 3 study." Douglas Love, President and CEO.
• "We are actively engaged in global regulatory interactions to bring tanruprubart to patients worldwide, which includes preparing to submit our Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in the first quarter of 2026." Douglas Love, President and CEO.
• "We are also increasingly excited by the positive momentum of vonaprument for dry age-related macular degeneration (AMD) with geographic atrophy (GA), exemplified by the accelerated enrollment of our Phase 3 ARCHER II trial coupled with the established global registration path to provide a potentially new vision preserving treatment for the eight million people with GA worldwide." Douglas Love, President and CEO.
• "We are on pace to deliver topline pivotal data in the second half of 2026." Douglas Love, President and CEO.
• "For our oral C1s inhibitor ANX1502, we are optimistic as the exposure demonstrated thus far has exceeded our target threshold in fasted patients without concomitant food intake." Douglas Love, President and CEO.
• "We remain disciplined with our financial and operational execution, and are capitalized into the fourth quarter of 2026 through our pivotal Phase 3 data in GA." Douglas Love, President and CEO.

Industry Context

Annexon operates in the highly competitive biopharmaceutical sector, specifically targeting neuroinflammatory diseases driven by the classical complement pathway. Its focus on C1q inhibition positions it in a niche within immunology and neurology, aiming to address significant unmet medical needs in conditions like GBS and dry AMD with GA, where current treatment options are limited or non-existent. The company's pipeline progress, particularly with late-stage assets, aligns with the industry trend of advancing novel mechanisms of action for complex diseases.

Comparison to Industry Standards

• The GBS Phase 3 results for Tanruprubart, showing 90% improvement by week 1 and over twice as many patients achieving normal health at week 26 vs. placebo, are presented as "unprecedented" and "favorable outcomes versus SOC" (standard of care) in the filing, suggesting strong comparative efficacy against existing limited treatments like immunoglobulin (IVIg) or plasma exchange.
• For dry AMD with GA, Vonaprument aims to be the "first treatment approved in both Europe and the U.S. for protection of vision," which would set a new standard in a disease affecting over eight million people worldwide with no approved vision-preserving therapies.
• The selection of Vonaprument for the EMA PRIME Product Development Candidate Pilot indicates recognition by a major regulatory body of its potential to address an unmet medical need and its scientific promise, a positive signal in line with high-potential drug candidates.
• ANX1502, as a "first-in-kind oral C1s inhibitor," represents a potential disruptive innovation in autoimmune diseases, offering the convenience of oral administration compared to existing biologic treatments, which are often injectables.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trials are successful and regulatory approvals are secured, but also risk from increasing losses and the need for future capital.
• Patients (GBS, Dry AMD with GA, CAD): Potential for new, effective treatments for devastating diseases with limited current options.
• Employees: Continued employment and potential growth opportunities as programs advance.
• Regulatory Authorities (FDA, EMA): Ongoing engagement and submissions for novel therapies.

Next Steps

• Submit Marketing Authorization Application (MAA) for Tanruprubart in Europe in the first quarter of 2026.
• Continue discussions with the FDA on the generalizability package to support a BLA submission for Tanruprubart.
• Seek further regulatory clarity on FDA BLA submission timing for Tanruprubart.
• Continue discussions with pharmaceutical companies regarding collaborating on the commercialization of tanruprubart for GBS in various geographies.
• Deliver topline Phase 3 ARCHER II trial data for Vonaprument in the second half of 2026.
• Provide an update on the ANX1502 proof-of-concept trial in CAD by year-end 2025.
• Evaluate PK/PD of ANX1502 in relation to food intake and reduction in complement and bilirubin markers.

Key Dates

Recommendation

While Annexon has demonstrated significant clinical progress with its late-stage pipeline, including positive Phase 3 data for Tanruprubart and accelerated enrollment for Vonaprument, the company's net loss and R&D expenses have substantially increased. The current cash runway extends into Q4 2026, covering key data readouts, but the increasing burn rate suggests that future capital raises will likely be necessary. The stock's performance will heavily depend on the success of upcoming clinical milestones and regulatory approvals, making it a 'hold' for investors awaiting further clarity on these pivotal events and the company's path to profitability.

Keywords

biopharmaceutical, neuroinflammatory diseases, Guillain-Barr Syndrome, GBS, dry age-related macular degeneration, AMD, geographic atrophy, GA, C1s inhibitor, ANX005, ANX007, ANX1502, clinical trials, Phase 3, FDA, EMA, biotech, drug development, complement system, rare diseases, ophthalmology, autoimmune conditions